A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ABIVAX operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - |
| Net Income | -190M | -190M | -160M | -64M | -50M |
| EPS | $-3.03 | $-3.03 | $-3.72 | $-3.35 | $-3.25 |
| Free Cash Flow | -167M | -167M | -106M | -57M | -53M |
| ROIC | -66.6% | -66.6% | -30.8% | -67.8% | -190.9% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.74 | 0.21 | 2.35 | 1.97 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -187M | -187M | -138M | -68M | -49M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -434.3% | -148.4% | -145.6% | -335.1% | -163.7% |
| Shares Outstanding | 63M | 63M | 43M | 19M | 15M |
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | -56M | -51M | -112M | -158M | -158M |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -49M | -68M | -138M | -187M | -187M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -50M | -64M | -160M | -190M | -190M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -190.9% | -67.8% | -30.8% | -66.6% | -66.6% |
| ROE | -163.7% | -335.1% | -145.6% | -148.4% | -434.3% |
| ROA | -38.9% | -61.4% | -73.8% | -66.0% | -85.9% |
| Cash Flow | |||||
| Op. Cash Flow | -53M | -57M | -105M | -166M | -166M |
| Free Cash Flow | -53M | -57M | -106M | -167M | -167M |
| Owner Earnings | -54M | -59M | -115M | -190M | -190M |
| CapEx | 55K | 303K | 288K | 691K | 691K |
| Maint. CapEx | 356K | 511K | 768K | 1.2M | 1.2M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 |
| D&A | 356K | 511K | 768K | 1.2M | 1.2M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 149K | 29K | 11K | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 977K | 1.2M | 8.9M | 22M | 22M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | -11M | -11M | -230M | -79M | -156M |
| Cash & Equiv. | 72M | 28M | 274M | 156M | 156M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 1.97 | 2.35 | 0.21 | 1.74 | 0.00 |
| Interest Coverage | -11.6 | -9.2 | -4.6 | -10.2 | -10.2 |
| Equity | 31M | 7.6M | 213M | 44M | 44M |
| Total Assets | 129M | 80M | 355M | 222M | 222M |
| Total Liabilities | 98M | 72M | 142M | 178M | 178M |
| Intangibles | N/A | 7.0M | 7.2M | 7.1M | 7.1M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 51M | -16M | 212M | 83M | 83M |
| Current Assets | 89M | 38M | 310M | 184M | 184M |
| Current Liabilities | 38M | 54M | 98M | 102M | 102M |
| Per Share Data | |||||
| EPS | -3.25 | -3.35 | -3.72 | -3.03 | -3.03 |
| Owner EPS | -3.53 | -3.06 | -2.67 | -3.01 | -3.01 |
| Book Value | 1.98 | 0.40 | 4.94 | 0.70 | 0.70 |
| Cash Flow/Share | -3.44 | -2.97 | -2.45 | -2.64 | -3.01 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 15.4M | 19.1M | 43.1M | 62.9M | 62.9M |
| Valuation | |||||
| P/E Ratio | -9.1 | -2.0 | -2.9 | -2.4 | -35.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 15.0 | 16.8 | 2.2 | 10.5 | 154.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -11.6% | -45.0% | -22.6% | -36.2% | -2.5% |
| Market Cap | 458M | 127M | 468M | 462M | 6.8B |
| Avg. Price | 32.34 | 15.67 | 13.07 | 11.97 | 107.90 |
| Year-End Price | 29.67 | 6.64 | 10.86 | 7.34 | 107.90 |
ABIVAX passes 0 of 9 quality checks, indicating weak fundamentals.
ABIVAX (ABVX-PA) has a 5-year average return on invested capital (ROIC) of -89.0%. This is below average and may indicate limited pricing power.
ABIVAX (ABVX-PA) has a market capitalization of $6.8B. It is classified as a mid-cap stock.
ABIVAX (ABVX-PA) does not currently pay a regular dividend.
ABIVAX (ABVX-PA) operates in the Biotechnology industry, within the Healthcare sector.
ABIVAX (ABVX-PA) generated $-167 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ABIVAX (ABVX-PA) has a debt-to-equity ratio of 1.74. This indicates higher leverage, which may increase financial risk.
ABIVAX (ABVX-PA) reported earnings per share (EPS) of $-3.03 in its most recent fiscal year.
ABIVAX (ABVX-PA) has a return on equity (ROE) of -148.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for ABIVAX (ABVX-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ABIVAX (ABVX-PA) has a book value per share of $0.70, based on its most recent annual SEC filing.
No recent press releases.